Holen Sie sich die Stockscreener-App
6.76
1.60%
-0.11
Handel nachbörslich:
6.76
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
Astria Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Signal strength of Astria Therapeutics Inc. stock in tech scannersVolume Spike & Pattern Based Trade Signal System - Newser
Can trapped investors hope for a rebound in Astria Therapeutics Inc.2025 Market Trends & Long-Term Growth Stock Strategies - Newser
Astria Therapeutics price target raised to $26 from $25 at Citizens JMP - MSN
Price action breakdown for Astria Therapeutics Inc.Earnings Recap Summary & Reliable Price Action Trade Plans - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Price Swings & Expert Verified Movement Alerts - Newser
Can Astria Therapeutics Inc. Regain Lost Ground This QuarterWeekly Trend Summary & Accurate Entry and Exit Point Alerts - metal.it
Long term hold vs stop loss in Astria Therapeutics Inc.Earnings Recap Summary & Daily Entry Point Alerts - Newser
Astria Therapeutics stock price target raised to $26 by JMP on HAE program progress - Investing.com Canada
Shining A Light On Astria Therapeutics As Its Atopic Dermatitis Drug Approaches A Key Milestone - RTTNews
Technical signs of recovery in Astria Therapeutics Inc.July 2025 Review & Entry Point Confirmation Alerts - Newser
Astria Therapeutics Inc. stock momentum explainedMarket Activity Summary & Technical Pattern Based Buy Signals - Newser
Can Astria Therapeutics Inc. hit a new high this monthWeekly Profit Report & AI Based Buy and Sell Signals - Newser
Applying sector rotation models to Astria Therapeutics Inc.Analyst Downgrade & Safe Capital Growth Plans - Newser
How high can Astria Therapeutics Inc. stock goRisk Aware Trading Ideas with Alert Levels - Newser
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - BioSpace
Astria Therapeutics Inc. stock prediction for this weekRisk Adjusted Trade Signal Screening Tool - Newser
what makes astria therapeutics inc. stock price move sharplyFree Sector Rotation Based Trading Opportunities - Newser
Astria Therapeutics, Inc. SEC 10-Q Report - TradingView
Is it time to cut losses on Astria Therapeutics Inc.Pre-Market Stock Movement Summary and Review - Newser
What earnings revisions data tells us about Astria Therapeutics Inc.Weekly Chart Watchlist with Trade Guidance - Newser
How to build a dashboard for Astria Therapeutics Inc. stockWeekly Market Direction and Sector Summary - Newser
Will Astria Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsFree Market Momentum and Signal Alerts - Newser
How Astria Therapeutics Inc. stock performs during market volatilityFree Momentum Based Equity Trading Plan - Newser
Is Astria Therapeutics Inc. showing signs of accumulationInvestment Roadmap for High Potential Stocks - Newser
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
Astria licenses rare disease drug Navenibart to Japan’s Kaken Pharma in $32 M deal - BioSpectrum Asia
Astria Therapeutics shares fall 1.15% intraday after being dropped from multiple Russell indices. - AInvest
Astria Therapeutics licenses navenibart rights to Kaken for HAE - Pharmaceutical Technology
How to escape a deep drawdown in Astria Therapeutics Inc.Chart Confirmation Setup with ROI Signals - Newser
Astria Therapeutics’ Strategic Advancements and Market Potential: A Buy Recommendation by Joseph Pantginis - TipRanks
Astria Therapeutics: Strategic Partnership and Promising Phase 3 Trial Justify Buy Rating - TipRanks
Astria Therapeutics Strikes Licensing Deal in Japan - MarketScreener
Astria Therapeutics Licenses Japan Rights to Navenibart in $16mln Deal, Kaken Pharmaceutical to Support Phase 3 Trials and Commercialization - AInvest
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):